The case for induced pluripotent stem cell‐derived cardiomyocytes in pharmacological screening
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The current drug screening models are deficient, particularly in detecting cardiac side effects. Human stem cell‐derived cardiomyocytes could aid both early cardiotoxicity detection and novel drug discovery. Work over the last decade has generated human embryonic stem cells as potentially accurate sources of human cardiomyocytes, but ethical constraints and poor efficacy in establishing cell lines limit their use. Induced pluripotent stem cells do not require the use of human embryos and have the added advantage of producing patient‐specific cardiomyocytes, allowing both generic and disease‐ and patient‐specific pharmacological screening, as well as drug development through disease modelling. A critical question is whether sufficient standards have been achieved in the reliable and reproducible generation of ‘adult‐like’ cardiomyocytes from human fibroblast tissue to progress from validation to safe use in practice and drug discovery. This review will highlight the need for a new experimental system, assess the validity of human induced pluripotent stem cell‐derived cardiomyocytes and explore what the future may hold for their use in pharmacology. LINKED ARTICLES This article is part of a themed section on Regenerative Medicine and Pharmacology: A Look to the Future. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.169.issue‐2
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167 · cited 3×
“Drug discovery and toxicology: the need for a new experimental system There is a vast attrition in the number of drugs developed for potential therapeutic use during the transition from the laboratory bench to hospital bedside, with 89% of drugs that pass current in vitro and animal model screening tests being withdra…”
BackgroundHuman induced pluripotent stem cells free of vector and transgene sequences
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2009) · Science · doi:10.1126/science.1172482 · Cited by 2,386
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196 · cited 3×
“A number of other groups have replicated this work showing that human somatic cells can be reprogrammed to a pluripotent state by forced expression of a small set of transcription factors (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007; Lowry et al., 2008; Park et al., 2008b).”
BackgroundCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“This has been a problem with monoclonal antibodies in other areas, such as the TGN1412 antibody, which produced unexpected cytokine storms in healthy human subjects (Suntharalingam et al., 2006).”
BackgroundMaherali, N., Sridharan, R., Xie, W., Utikal, J., Eminli, S., Arnold, K., Stadtfeld, M., Yachechko, R., Tchieu, J., Jaenisch, R., et al. (2007) · Cell stem cell · doi:10.1016/j.stem.2007.05.014 · Cited by 1,725 · cited 1×
“A number of other groups have replicated this work showing that human somatic cells can be reprogrammed to a pluripotent state by forced expression of a small set of transcription factors (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007; Lowry et al., 2008; Park et al., 2008b).”
BackgroundInduced pluripotent stem cells generated without viral integration
Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G., & Hochedlinger, K. (2008) · Science · doi:10.1126/science.1162494 · Cited by 1,683
FUSAKI, N., BAN, H., NISHIYAMA, A., SAEKI, K., & HASEGAWA, M. (2009) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.85.348 · Cited by 1,411 · cited 2×
“Other non-integrating approaches include using episomes (Yu et al., 2009), adenoviruses (Stadtfeld et al., 2008), RNA viruses (Fusaki et al., 2009) and plasmid transfection (Okita et al., 2008; Gonzalez et al., 2009).”
BackgroundHuman cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population
Yang, L., Soonpaa, M. H., Adler, E. D., Roepke, T. K., Kattman, S. J., Kennedy, M., Henckaerts, E., Bonham, K., Abbott, G. W., Linden, R. M., et al. (2008) · Nature · doi:10.1038/nature06894 · Cited by 1,389 · cited 4×
“…(Burridge et al., 2011; Xu et al., 2012), manipulation of Activin/ Nodal and Wnt signalling pathways as mentioned earlier (Laflamme et al., 2007; Yang et al., 2008; Kattman et al., 2011; Ren et al., 2011), and supplementing the culture media with chemical promoters of cardiac differentiation…”
BackgroundInfluentialPatient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908679 · Cited by 1,251
Kattman, S. J., Witty, A. D., Gagliardi, M., Dubois, N. C., Niapour, M., Hotta, A., Ellis, J., & Keller, G. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2010.12.008 · Cited by 1,159
Modelling the long QT syndrome with induced pluripotent stem cells
Itzhaki, I., Maizels, L., Huber, I., Zwi-Dantsis, L., Caspi, O., Winterstern, A., Feldman, O., Gepstein, A., Arbel, G., Hammerman, H., et al. (2011) · Nature · doi:10.1038/nature09747 · Cited by 1,049
Generation of human induced pluripotent stem cells from dermal fibroblasts
Lowry, W. E., Richter, L., Yachechko, R., Pyle, A. D., Tchieu, J., Sridharan, R., Clark, A. T., & Plath, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711983105 · Cited by 1,041 · cited 1×
“A number of other groups have replicated this work showing that human somatic cells can be reprogrammed to a pluripotent state by forced expression of a small set of transcription factors (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007; Lowry et al., 2008; Park et al., 2008b).”
BackgroundHe, J.-Q., Ma, Y., Lee, Y., Thomson, J. A., & Kamp, T. J. (2003) · Circulation Research · doi:10.1161/01.res.0000080317.92718.99 · Cited by 800 · cited 2×
“A major criticism is that hESC-CMs resemble fetal rather than adult cardiomyocytes in appearance, structure and function (He et al., 2003; Mummery et al., 2003; Brito-Martins et al., 2008; Caspi et al., 2009; Braam et al., 2010).”
BackgroundPatient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome
Carvajal-Vergara, X., Sevilla, A., D’Souza, S. L., Ang, Y.-S., Schaniel, C., Lee, D.-F., Yang, L., Kaplan, A. D., Adler, E. D., Rozov, R., et al. (2010) · Nature · doi:10.1038/nature09005 · Cited by 690 · cited 1×
“This model has been used to further understand the molecular mechanisms underlying the disease, implicating disruption of the RAS–MAPK pathway as evidenced by up regulation of the phosphoprotein MEK1, an upstream kinase of ERK1/2 (Carvajal-Vergara et al., 2010).”
MethodUsing induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome
Yazawa, M., Hsueh, B., Jia, X., Pasca, A. M., Bernstein, J. A., Hallmayer, J., & Dolmetsch, R. E. (2011) · Nature · doi:10.1038/nature09855 · Cited by 677
Technical Challenges in Using Human Induced Pluripotent Stem Cells to Model Disease
Saha, K., & Jaenisch, R. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.11.009 · Cited by 411 · cited 1×
“Furthermore, these methods are often extremely labour intensive and inefficient (Saha and Jaenisch, 2009).”
MethodMatsa, E., Rajamohan, D., Dick, E., Young, L., Mellor, I., Staniforth, A., & Denning, C. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr073 · Cited by 389
Marbán, E. (2002) · Nature · doi:10.1038/415213a · Cited by 328
Liu, J., Fu, J. D., Siu, C. W., & Li, R. A. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0549 · Cited by 186
Germanguz, I., Sedan, O., Zeevi‐Levin, N., Shtrichman, R., Barak, E., Ziskind, A., Eliyahu, S., Meiry, G., Amit, M., Itskovitz‐Eldor, J., et al. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00996.x · Cited by 160 · cited 6×
“This functional calcium-induced calcium release mechanism is similar to that found in human cardiomyocytes (Cannell et al., 1995; Bers, 2002), though the response of hiPSC-CMs to ryanodine and caffeine is less in magnitude than that of human adult cardiomyocytes (Germanguz et al., 2011).”
BackgroundResultInfluentialThe human embryonic stem cell-derived cardiomyocyte as a pharmacological model
Harding, S. E., Ali, N. N., Brito-Martins, M., & Gorelik, J. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.008 · Cited by 84 · cited 2×
“…calcium handling, receptor response, growth, proliferation and survival, showing similarities to human cardiomyocytes (Reppel et al., 2004; Harding et al., 2007; Liu et al., 2007; Sartiani et al., 2007; Brito-Martins et al., 2008; Habib et al., 2008; Pekkanen-Mattila et al., 2010).”
BackgroundSelf-citationMEIRY, G., REISNER, Y., FELD, Y., GOLDBERG, S., ROSEN, M., ZIV, N., & BINAH, O. (2001) · Journal of Cardiovascular Electrophysiology · doi:10.1046/j.1540-8167.2001.01269.x · Cited by 77
Brito‐Martins, M., Harding, S. E., & Ali, N. N. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707619 · Cited by 74
Self-citationLian, Q., Chow, Y., Esteban, M., Pei, D., & Tse, H.-F. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-05-0269 · Cited by 55 · cited 3×
“Lastly, the predictability of transgenic mouse models for diseases such as hypertrophic cardiomyopathy and Brugada syndrome are limited due to rodent heart size and electrophysiology, so alternative models are needed for testing disease specific therapies and toxicities (Lian et al., 2010).”
BackgroundInfluential
Cited by
Human iPSC-based modeling of late-onset disease via progerin-induced aging
Miller, J. D., Ganat, Y. M., Kishinevsky, S., Bowman, R. L., Liu, B., Tu, E. Y., Mandal, P. K., Vera, E., Shim, J.-W., Kriks, S., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.11.006 · Cited by 777
Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes
Giacomelli, E., Mummery, C. L., & Bellin, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2546-5 · Cited by 60
“Furthermore, they show similar functional properties to the cardiomyocytes in the developing heart, such as comparable dose-dependent response to cardiac drugs in terms of beating frequency and contractility, b-adrenoreceptor responses, action potential (AP) morphologies, and excitation–contraction coupling mechanisms…”
BackgroundBack and forth in time: Directing age in iPSC-derived lineages
Cornacchia, D., & Studer, L. (2017) · Brain Research · doi:10.1016/j.brainres.2015.11.013 · Cited by 56
Metadata
- Authors
- Khan, J. M., Lyon, A. R., & Harding, S. E.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2013-04-25
- Volume
- 169
- Issue
- 2
- Pages
- 304-317
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2168235673
- Cited by
- 63
- References
- 24
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.